Support our Foundation of Myology project
CLINICAL ACTIVITIES
Ongoing trials
The Institute of Myology leads cutting-edge clinical trials for neuromuscular diseases, in partnership with industry laboratories and academic researchers.
Below you will find the list of ongoing trials at the Institute of Myology
75 clinical trials in progress
ADSVF-in-IBM – Cell therapy in inclusion body myositis
Intramuscular injection of autologous cells from the stromal vascular fraction of adipose tissue: a phase 1 trial.
ADSVF-in-IBM – Cell therapy in inclusion body myositis
Intramuscular injection of autologous cells from the stromal vascular fraction of adipose tissue: a phase 1 trial.
- Code
- ADSVF-in-IBM
- Disease
- Myositis
- Principal investigator
- O. Benveniste
- Sponsor
- APHP (PHRC)
- Status
- Active
- Public
- Adults
- Phase
- Phase 1
- Trial site
- I-Motion Adults
GNT-014-MDYF – Natural history of DMD
A prospective, interventional, reference study examining the natural history of DMD in young male patients aged 4 to 6 years.
GNT-014-MDYF – Natural history of DMD
A prospective, interventional, reference study examining the natural history of DMD in young male patients aged 4 to 6 years.
- Code
- GNT-014-MDYF
- Disease
- Duchenne muscular dystrophy
- Principal investigator
- Silvana De Lucia
- Sponsor
- Genethon
- Status
- Active
- Public
- Paediatric
- Trial site
- I-Motion Pediatric
IgPro20_3007 – RECLAIIM study
Assessment of the efficacy, safety and pharmacokinetics of IgPro20 in adults with dermatomyositis.
IgPro20_3007 – RECLAIIM study
Assessment of the efficacy, safety and pharmacokinetics of IgPro20 in adults with dermatomyositis.
- Code
- IgPro20_3007
- Disease
- Myositis
- Principal investigator
- O. Benveniste
- Sponsor
- CSL Behring
- Status
- Active
- Public
- Adults
- Trial site
- I-Motion Adults
UMD-DMD – Dystrophinopathy database
Dystrophinopathy database bringing together the French molecular diagnostic laboratories and all the neuromuscular reference and competence centres.
UMD-DMD – Dystrophinopathy database
Dystrophinopathy database bringing together the French molecular diagnostic laboratories and all the neuromuscular reference and competence centres.
- Code
- UMD-DMD
- Disease
- Duchenne muscular dystrophy
- Principal investigator
- Rabah Ben Yaou / France Leturcq / Sylvie Tuffery-Giraud
- Sponsor
- Laboratoires francais de diagnostic moleculaire des dystrophinopathies + tous les centres de reference et competence MNM
- Status
- Ongoing
- Public
- Adults, Paediatric
Echostim-EFR
Ultrafast ultrasound for the functional assessment of the diaphragm: agreement with standard mechanical and electrophysiological variables, and diagnostic performance.
Echostim-EFR
Ultrafast ultrasound for the functional assessment of the diaphragm: agreement with standard mechanical and electrophysiological variables, and diagnostic performance.
- Code
- Echostim-EFR
- Disease
- Cross-disease studies
- Principal investigator
- Damien Bachasson
- Sponsor
- AIM
- Status
- Active
- Public
- Adults
- Trial site
- I-Motion Adults
AVXS-101-LT-002
Long-term follow-up study of patients who received AVXS-101 in the clinical trials for spinal muscular atrophy.
AVXS-101-LT-002
Long-term follow-up study of patients who received AVXS-101 in the clinical trials for spinal muscular atrophy.
- Code
- AVXS-101-LT-002
- Disease
- Spinal muscular atrophies
- Principal investigator
- Andreea Seferian
- Sponsor
- AveXis
- Status
- Active
- Public
- Paediatric
- Trial site
- I-Motion Pediatric
AZA-001-301
An 18-month, multicentre, phase 3, double-blind, randomised, placebo-controlled study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of Niemann-Pick disease type C and in late-infantile and juvenile forms of GM1 or GM2 gangliosidosis.
AZA-001-301
An 18-month, multicentre, phase 3, double-blind, randomised, placebo-controlled study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of Niemann-Pick disease type C and in late-infantile and juvenile forms of GM1 or GM2 gangliosidosis.
- Code
- AZA-001-301
- Disease
- Gangliosidosis
- Principal investigator
- Benedicte Heron
- Sponsor
- Azafaros
- Status
- In preparation
- Public
- Paediatric
- Phase
- Phase 3
- Trial site
- I-Motion Pediatric
ONYX
An open-label, multicentre extension study to evaluate the long-term safety and efficacy of apitegromab in patients with type 2 and type 3 spinal muscular atrophy who took part in previous apitegromab studies.
ONYX
An open-label, multicentre extension study to evaluate the long-term safety and efficacy of apitegromab in patients with type 2 and type 3 spinal muscular atrophy who took part in previous apitegromab studies.
- Code
- ONYX
- Disease
- Spinal muscular atrophies
- Principal investigator
- Andreea Seferian
- Sponsor
- Scholar Rock
- Status
- Active
- Public
- Paediatric
- Trial site
- I-Motion Pediatric
GSD3 – Prospective patient follow-up
An observational study with prospective follow-up of patients with glycogen storage disease type III.
GSD3 – Prospective patient follow-up
An observational study with prospective follow-up of patients with glycogen storage disease type III.
- Code
- GSD3
- Disease
- Glycogen storage disease type III
- Principal investigator
- P. Laforet et P. Labrune
- Sponsor
- AIM
- Status
- Active
- Public
- Adults
PHENO SMART
Characterisation of new phenotypes in patients with type 1, 2 and 3 infantile or juvenile spinal muscular atrophy treated with therapies that restore SMN protein expression.
PHENO SMART
Characterisation of new phenotypes in patients with type 1, 2 and 3 infantile or juvenile spinal muscular atrophy treated with therapies that restore SMN protein expression.
- Code
- PHENO SMART
- Disease
- Spinal muscular atrophies
- Principal investigator
- Silvana De Lucia
- Sponsor
- UCL
- Status
- In preparation
- Public
- Paediatric
- Trial site
- I-Motion Pediatric
PTA17333 Avaglucosidase
A French multicentre, phase 4, open-label extension study of long-term safety and efficacy in patients with Pompe disease who previously took part in development studies.
PTA17333 Avaglucosidase
A French multicentre, phase 4, open-label extension study of long-term safety and efficacy in patients with Pompe disease who previously took part in development studies.
- Code
- PTA17333 Avaglucosidase
- Disease
- Glycogen storage disease type II (Pompe disease)
- Principal investigator
- Anthony Behin
- Sponsor
- Sanofi
- Status
- Active
- Public
- Adults
- Phase
- Phase 4
- Trial site
- I-Motion Adults
Manatee Roche
A two-part, multicentre, randomised, placebo-controlled, double-blind study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7204239 in combination with risdiplam in patients with spinal muscular atrophy.
Manatee Roche
A two-part, multicentre, randomised, placebo-controlled, double-blind study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7204239 in combination with risdiplam in patients with spinal muscular atrophy.
- Code
- Manatee Roche
- Disease
- Spinal muscular atrophies
- Principal investigator
- Silvana De Lucia
- Sponsor
- Roche
- Status
- In preparation
- Public
- Paediatric
- Trial site
- I-Motion Pediatric
French Pompe disease registry
French registry for the follow-up of patients with Pompe disease and the collection of data on them.
French Pompe disease registry
French registry for the follow-up of patients with Pompe disease and the collection of data on them.
- Code
- Registre-FR-Pompe
- Disease
- Glycogen storage disease type II (Pompe disease)
- Principal investigator
- Pascal Laforet
- Sponsor
- Institut de Myologie
- Status
- Active
- Public
- Adults
SRK-015-005 – OPALE
A phase 2 study evaluating the pharmacokinetics, pharmacodynamics, efficacy and safety of apitegromab in participants under 2 years of age with spinal muscular atrophy.
SRK-015-005 – OPALE
A phase 2 study evaluating the pharmacokinetics, pharmacodynamics, efficacy and safety of apitegromab in participants under 2 years of age with spinal muscular atrophy.
- Code
- SRK-015-005 – OPALE
- Disease
- Spinal muscular atrophies
- Principal investigator
- Andreea Seferian
- Sponsor
- Scholar Rock
- Status
- In preparation
- Public
- Paediatric
- Phase
- Phase 2
- Trial site
- I-Motion Pediatric
International Pompe disease registry
International registry for the follow-up of patients with Pompe disease.
International Pompe disease registry
International registry for the follow-up of patients with Pompe disease.
- Code
- Registre-INT-Pompe
- Disease
- Glycogen storage disease type II (Pompe disease)
- Principal investigator
- Pascal Laforet (pour la France)
- Sponsor
- Sanofi
- Status
- Active
- Public
- Adults
R-SMA
A retrospective study of the natural history of the disease and real-world assessment of the effect of treatments in patients with spinal muscular atrophy.
R-SMA
A retrospective study of the natural history of the disease and real-world assessment of the effect of treatments in patients with spinal muscular atrophy.
- Code
- R-SMA
- Disease
- Spinal muscular atrophies
- Principal investigator
- Tanya Stojkovic
- Sponsor
- APHP
- Status
- Active
- Public
- Adults
UMD-EMD – Emerinopathy database
Non-interventional data collection on emerinopathies, gathering medical information and following the progression of patients with Emery-Dreifuss muscular dystrophy.
UMD-EMD – Emerinopathy database
Non-interventional data collection on emerinopathies, gathering medical information and following the progression of patients with Emery-Dreifuss muscular dystrophy.
- Code
- UMD-EMD
- Disease
- Laminopathies and emerinopathies
- Principal investigator
- France Leturcq, Rabah Ben Yaou
- Sponsor
- Laboratoire de biochimie et genetique moleculaire GH Cochin + Centres de Reference des maladies neuromusculaires + Centre de recherche en myologie Institut de Myologie
- Status
- Ongoing
- Public
- Adults
NH-SMA / SMOB
Outcome measures and biomarkers in a cohort of patients with type 3 or type 4 spinal muscular atrophy (SMA).
NH-SMA / SMOB
Outcome measures and biomarkers in a cohort of patients with type 3 or type 4 spinal muscular atrophy (SMA).
- Code
- NH-SMA / SMOB
- Disease
- Spinal muscular atrophies
- Principal investigator
- Tanya Stojkovic
- Sponsor
- APHM
- Status
- Active
- Public
- Adults
UMD-LMNA – Laminopathy database
Non-interventional data collection on laminopathies, gathering medical information and following the progression of patients with Emery-Dreifuss muscular dystrophy.
UMD-LMNA – Laminopathy database
Non-interventional data collection on laminopathies, gathering medical information and following the progression of patients with Emery-Dreifuss muscular dystrophy.
- Code
- UMD-LMNA
- Disease
- Laminopathies and emerinopathies
- Principal investigator
- Gisele Bonne, Rabah Ben Yaou
- Sponsor
- Centre de recherche en myologie Institut de Myologie + UF de Cardiogenetique et Myogenetique Moleculaire et Cellulaire
- Status
- Ongoing
- Public
- Adults
PTC-AADC-MA-406
A two-part, international, real-world observational registry of participants diagnosed with aromatic L-amino acid decarboxylase (AADC) deficiency, with or without treatment with eladocagene exuparvovec.
PTC-AADC-MA-406
A two-part, international, real-world observational registry of participants diagnosed with aromatic L-amino acid decarboxylase (AADC) deficiency, with or without treatment with eladocagene exuparvovec.
- Code
- PTC-AADC-MA-406
- Disease
- AADC deficiency
- Principal investigator
- Claudia Ravelli
- Sponsor
- PTC Therapeutics
- Status
- Active
- Public
- Paediatric
